Biol Blood Marrow Transplant. 2009 May;15(5):523-36. Epub 2009 Feb 12.

Busulfan in hematopoietic stem cell transplantation.

Source

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Abstract

The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.

PMID:: 19361744; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Molecular Biology Databases

BUSULFAN - HSDB

Supplemental Content

Save items

Related citations in PubMed

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. [Biol Blood Marrow Transplant. ...]
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, et al. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. [J Hematol Oncol. 2010]
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. J Hematol Oncol. 2010 Oct 6; 3:36. Epub 2010 Oct 6.
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. [Curr Opin Oncol. 2009]
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Curr Opin Oncol. 2009 Jun; 21 Suppl 1:S11-5.
Review Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? [Exp Hematol. 2003]
Review Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned?
Ferry C, Socié G. Exp Hematol. 2003 Dec; 31(12):1182-6.
Review Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. [Expert Rev Anticancer Ther. 2008]
Review Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Lekakis L, de Lima M. Expert Rev Anticancer Ther. 2008 May; 8(5):785-98.

See reviews... See all...

Cited by 4 PubMed Central articles

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. [Korean J Hematol. 2010]
Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide.
Lee JH, Choi J, Kwon KA, Lee S, Oh SY, Kwon HC, Kim HJ, Han JY, Kim SH. Korean J Hematol. 2010 Jun; 45(2):102-8. Epub 2010 Jun 30.
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. [Biochem Pharmacol. 2011]
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. Biochem Pharmacol. 2011 Jan 15; 81(2):222-32. Epub 2010 Oct 8.
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. [Haematologica. 2010]
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, de la Rubia J, Rosiñol L, Sureda A, García-Laraña J, Díaz-Mediavilla J, Hernández-García MT, et al. Haematologica. 2010 Nov; 95(11):1913-20. Epub 2010 Jul 27.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Busulfan in hematopoietic stem cell transplantation.
Busulfan in hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2009 May ;15(5):523-36. Epub 2009 Feb 12 .

PubMed
Effect of trichloroethylene (TCE) toxicity on the enzymes of carbohydrate metabo...
Effect of trichloroethylene (TCE) toxicity on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in kidney and other rat tissues.
Food Chem Toxicol. 2009 Jul ;47(7):1562-8. Epub 2009 Apr 8 .

PubMed
Gonadectomy negatively impacts social behavior of adolescent male primates.
Gonadectomy negatively impacts social behavior of adolescent male primates.
Horm Behav. 2009 Jun ;56(1):140-8. Epub 2009 Apr 8 .

PubMed
Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of ...
Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest.
Brain Res. 2009 Oct 13 ;1293:108-13. Epub 2009 Apr 8 .

PubMed
Vertical facial growth: a longitudinal study from 7 to 14 years of age.
Vertical facial growth: a longitudinal study from 7 to 14 years of age.
Eur J Orthod. 1991 Jun ;13(3):202-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: